• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Tregitopes: The active ingredient in IVIG-mediated tolerance induction?

Tregitopes: The active ingredient in IVIG-mediated tolerance induction?

by Adam | Oct 21, 2016

Antigen-specific tolerance induction by Tregitopes in vivo

Antigen-specific tolerance induction by Tregitopes in vivo

by Adam | Oct 21, 2016

Tregitope Applications to Tolerance Induction in Autoimmune Disease and Therapeutic Protein Immunogenicity

Tregitope Applications to Tolerance Induction in Autoimmune Disease and Therapeutic Protein Immunogenicity

by Adam | Oct 21, 2016

Albumin Delivery of Tregitope Peptides for Tolerance Induction in Autoimmunity and Inflammatory Disease

Albumin Delivery of Tregitope Peptides for Tolerance Induction in Autoimmunity and Inflammatory Disease

by Adam | Oct 21, 2016

In silico High Throughput Pre-clinical Determination of Monoclonal Antibody Immunogenicity

In silico High Throughput Pre-clinical Determination of Monoclonal Antibody Immunogenicity

by Adam | Oct 21, 2016

« Older Entries
Next Entries »

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

  1. Homepage on Doing Well and Giving Back in December

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.